CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Sino Biopharmaceutical Limited - 1177 CFD

    3.42
    0.58%
    0.12
    Low: 3.38
    High: 3.44
    Market Trading Hours* (UTC) Open now
    Closes on Wednesday at 08:00

    Mon - Fri: 01:30 - 04:00 05:00 - 08:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.12
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.025961 %
    Charges from full value of position ($-4.93)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.025961%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004043 %
    Charges from full value of position ($0.77)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004043%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency HKD
    Margin 5%
    Stock exchange Hong Kong
    Commission on trade 0%

    *Information provided by Capital.com

    Sino Biopharmaceutical Ltd ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 3.44
    Open* 3.44
    1-Year Change* -23.89%
    Day's Range* 3.38 - 3.44
    52 wk Range 2.57-5.00
    Average Volume (10 days) 86.99M
    Average Volume (3 months) 1.20B
    Market Cap 70.88B
    P/E Ratio 35.59
    Shares Outstanding 18.80B
    Revenue 31.54B
    EPS 0.11
    Dividend (Yield %) 2.12202
    Beta 0.71
    Next Earnings Date Mar 29, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 6, 2023 3.42 0.00 0.00% 3.42 3.44 3.36
    Dec 5, 2023 3.44 -0.02 -0.58% 3.46 3.54 3.40
    Dec 4, 2023 3.48 -0.24 -6.45% 3.72 3.74 3.46
    Dec 1, 2023 3.66 -0.12 -3.17% 3.78 3.80 3.66
    Nov 30, 2023 3.78 0.12 3.28% 3.66 3.82 3.60
    Nov 29, 2023 3.66 -0.10 -2.66% 3.76 3.82 3.66
    Nov 28, 2023 3.76 0.08 2.17% 3.68 3.78 3.62
    Nov 27, 2023 3.68 -0.08 -2.13% 3.76 3.76 3.66
    Nov 24, 2023 3.70 -0.08 -2.12% 3.78 3.80 3.68
    Nov 23, 2023 3.80 0.08 2.15% 3.72 3.82 3.70
    Nov 22, 2023 3.72 -0.02 -0.53% 3.74 3.74 3.66
    Nov 21, 2023 3.74 -0.04 -1.06% 3.78 3.80 3.70
    Nov 20, 2023 3.76 -0.04 -1.05% 3.80 3.82 3.72
    Nov 17, 2023 3.78 0.18 5.00% 3.60 3.80 3.60
    Nov 16, 2023 3.70 -0.04 -1.07% 3.74 3.76 3.60
    Nov 15, 2023 3.76 0.12 3.30% 3.64 3.78 3.64
    Nov 14, 2023 3.60 0.00 0.00% 3.60 3.66 3.54
    Nov 13, 2023 3.60 0.18 5.26% 3.42 3.60 3.38
    Nov 10, 2023 3.38 -0.02 -0.59% 3.40 3.40 3.32
    Nov 9, 2023 3.46 -0.04 -1.14% 3.50 3.52 3.42

    Sino Biopharmaceutical Limited Events

    Time (UTC) Country Event
    Friday, March 29, 2024

    Time (UTC)

    10:59

    Country

    HK

    Event

    Full Year 2023 Sino Biopharmaceutical Ltd Earnings Release
    Full Year 2023 Sino Biopharmaceutical Ltd Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 28780.4 26861.4 23647.2 24234 20888.6
    Revenue 28780.4 26861.4 23647.2 24234 20888.6
    Cost of Revenue, Total 5795.51 5332.1 5182.32 4926.27 4196.93
    Gross Profit 22984.9 21529.3 18464.9 19307.8 16691.7
    Total Operating Expense 22409.8 21610.9 18307.6 18424.9 9366.15
    Selling/General/Admin. Expenses, Total 12564 12763.6 11628.6 11797 10268
    Interest Expense (Income) - Net Operating -172.512 -1110.37 -963.72 -561.3 -568.428
    Unusual Expense (Income) 25.527 639.276 -4.58 -0.903 -6557.24
    Other Operating Expenses, Total -55.912 308.971 -161.711 -134.863 -63.724
    Operating Income 6370.64 5250.5 5339.65 5809.16 11522.4
    Interest Income (Expense), Net Non-Operating -592.034 13322.2 -326.601 -118.565 -93.354
    Net Income Before Taxes 5778.6 18572.7 5013.04 5690.59 11429.1
    Net Income After Taxes 5002.62 16614.8 4340.67 4787.85 10732.8
    Minority Interest -2459.05 -2006.38 -1569.58 -2026.3 -1686.5
    Net Income Before Extra. Items 2543.57 14608.4 2771.09 2761.54 9046.35
    Net Income 2543.57 14608.4 2771.09 2761.54 9046.35
    Income Available to Common Excl. Extra. Items 2543.57 14608.4 2771.09 2761.54 9046.35
    Income Available to Common Incl. Extra. Items 2543.57 14608.4 2771.09 2761.54 9046.35
    Diluted Net Income 2311.2 14125.9 2771.09 2761.54 9046.35
    Diluted Weighted Average Shares 19017.2 19283 18800.3 18811.1 18548.5
    Diluted EPS Excluding Extraordinary Items 0.12153 0.73256 0.1474 0.1468 0.48771
    Dividends per Share - Common Stock Primary Issue 0.10598 0.06519 0.06172 0.04766 0.04292
    Diluted Normalized EPS 0.12269 0.76241 0.14719 0.14743 0.15597
    Research & Development 4253.15 3677.26 2626.71 2398.71 2090.57
    Dilution Adjustment -232.37 -482.511
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total revenue 15277 13586.7 15193.7 26861.4 7110.79
    Revenue 15277 13586.7 15193.7 26861.4 7110.79
    Cost of Revenue, Total 3256.5 2835.91 2959.6 5332.1 1337.41
    Gross Profit 12020.5 10750.8 12234.1 21529.3 5773.38
    Total Operating Expense 11529.3 10636.8 11773 21610.9 5006.58
    Selling/General/Admin. Expenses, Total 6444.36 5630.1 6933.9 12703.6 3180.71
    Research & Development 2357.26 2204.55 2048.6 3677.26 767.055
    Interest Expense (Income) - Net Operating -313.83 17.194 -189.706 -818.075 -181.424
    Unusual Expense (Income) -14.761 -1.162 7.288 -3.731 -0.794
    Other Operating Expenses, Total -200.24 -49.832 13.321 719.681 -96.374
    Operating Income 3747.74 2949.91 3420.73 5250.5 2104.21
    Interest Income (Expense), Net Non-Operating -523.575 -925.918 333.884 13322.2 6032.95
    Net Income Before Taxes 3224.17 2023.99 3754.61 18572.7 8137.16
    Net Income After Taxes 2699.42 1819.4 3183.22 16614.8 7247.19
    Minority Interest -1440.64 -1196.86 -1262.18 -2006.38 -680.348
    Net Income Before Extra. Items 1258.78 622.533 1921.04 14608.4 6566.84
    Net Income 1258.78 622.533 1921.04 14608.4 6566.84
    Income Available to Common Excl. Extra. Items 1258.78 622.533 1921.04 14608.4 6566.84
    Income Available to Common Incl. Extra. Items 1258.78 622.533 1921.04 14608.4 6566.84
    Diluted Net Income 1258.78 551.1 1760.1 14125.9 6566.84
    Diluted Weighted Average Shares 18564.2 18911.7 19122.7 19283 19289.1
    Diluted EPS Excluding Extraordinary Items 0.06781 0.02914 0.09204 0.73256 0.34044
    Dividends per Share - Common Stock Primary Issue 0.01851 0.05299 0.05122 0.03259 0.01663
    Diluted Normalized EPS 0.06714 0.02909 0.09237 0.73258 0.34041
    Dilution Adjustment -71.433 -160.937 -482.511
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 25934.9 23503.2 22794.2 24913.1 18538.1
    Cash and Short Term Investments 16921.7 15794.1 16431.8 19105.6 13022.7
    Cash 6413.98 6213.97 6596.5 4340.18 3956.99
    Cash & Equivalents 2240.82 3385.56 4027.69 6291.03 2278.04
    Short Term Investments 8266.86 6194.51 5807.63 8474.34 6787.64
    Total Receivables, Net 6218.71 5537.26 4075.75 3342.97 3865.17
    Accounts Receivable - Trade, Net 4638.4 4220.67 2914.08 2712.21 2924.04
    Total Inventory 2328.84 1937.74 1880.05 1658.6 1209.16
    Prepaid Expenses 465.687 234.127 406.578 805.972 404.009
    Other Current Assets, Total 37.116
    Total Assets 64064.3 60543.3 47210.4 37514.2 49780.2
    Property/Plant/Equipment, Total - Net 9251.18 8516.06 8392.2 7633.22 5804.37
    Property/Plant/Equipment, Total - Gross 13858.3 12490.9 11475.9 10013.8 7176.27
    Accumulated Depreciation, Total -4607.08 -3974.82 -3083.65 -2380.6 -1371.91
    Goodwill, Net 662.611 647.93 88.926 88.926 13897
    Intangibles, Net 1251.84 1064.02 924.71 1324.21 8349.17
    Long Term Investments 25950.3 25875.1 11215.4 2582.92 1437.27
    Other Long Term Assets, Total 1013.41 937.04 3795.02 971.814 1754.29
    Total Current Liabilities 20150.7 15345 10943.5 8123.02 9668.62
    Accounts Payable 1637.35 1693.15 1947.8 1809.44 1832.17
    Accrued Expenses 6299.15 5145.84 4190.39 3560.56 3252.42
    Notes Payable/Short Term Debt 136.13 136.13 0 0 0
    Current Port. of LT Debt/Capital Leases 9723.84 6585.04 1581.52 689.828 2905.57
    Other Current Liabilities, Total 2354.2 1784.86 3223.82 2063.19 1678.46
    Total Liabilities 34317.2 30252.2 30463.3 22564.9 20567.4
    Total Long Term Debt 4258.12 5685.27 13067.5 7926.07 507.066
    Long Term Debt 3933.86 5365.32 12802.6 7884.8 507.066
    Deferred Income Tax 831.791 881.59 171.652 423.261 1522.06
    Minority Interest 8196.51 7437.91 5672.4 5611.94 8336.69
    Other Liabilities, Total 880.146 902.433 608.201 480.652 532.941
    Total Equity 29747 30291.1 16747.2 14949.2 29212.8
    Common Stock 414.899 415.44 415.895 278.451 278.846
    Additional Paid-In Capital 12461.4 12555.7 12668.7 12944.4 13020.5
    Retained Earnings (Accumulated Deficit) 19070.3 17926.7 4087.38 2435.23 16462.1
    Unrealized Gain (Loss) 93.701 533.078 400.958 37.067 287.199
    Other Equity, Total -860.86 -450.393 -355.848 -333.099 -378.576
    Total Liabilities & Shareholders’ Equity 64064.3 60543.3 47210.4 37514.2 49780.2
    Total Common Shares Outstanding 18468.1 18839.6 18861.5 18882.4 18910.1
    Treasury Stock - Common -1432.48 -689.347 -469.944 -412.837 -457.288
    Capital Lease Obligations 324.263 319.949 264.861 41.27
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total Current Assets 26977.3 25934.9 25197.8 23503.2 23813.3
    Cash and Short Term Investments 15676.4 16921.7 15674.8 15224.6 10443.3
    Cash 2821.84 6413.98 4212.46 6213.97 5576.28
    Cash & Equivalents 472.126 2240.82 1852.99 3385.56 2452.05
    Short Term Investments 12382.4 8266.86 9609.39 5625.01 2415.02
    Total Receivables, Net 7188.86 5021.14 5354.76 4625.43 5174.74
    Accounts Receivable - Trade, Net 7108.97 4638.4 4947.84 4220.67 5059.33
    Total Inventory 2018.5 2328.84 2137.13 1937.74 1731.6
    Prepaid Expenses 2093.51 1663.26 2031.04 1715.45 6463.63
    Total Assets 65640.9 64064.3 64934.5 60543.3 56206.7
    Property/Plant/Equipment, Total - Net 9584.25 9251.18 8772.48 8516.06 8726.67
    Goodwill, Net 812.083 662.611 642.552 647.93 906.031
    Intangibles, Net 2129.61 1251.84 1214.07 1064.02 915.743
    Long Term Investments 24977 25950.3 28168.1 25875.1 17467.1
    Other Long Term Assets, Total 1160.69 1013.41 939.52 937.04 4377.86
    Total Current Liabilities 26865.4 20150.7 16265.5 15345 11485.5
    Accounts Payable 2137.21 1637.35 2676.47 1693.15 1620.73
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 10522.7 9723.84 4118.2 6585.04 1845.84
    Other Current Liabilities, Total 14205.5 8789.49 9470.83 7066.83 8018.92
    Total Liabilities 35651.6 34317.2 34720.3 30252.2 31631.1
    Total Long Term Debt 1031.34 4258.12 7983.31 5685.27 12258.7
    Long Term Debt 702.094 3933.86 7627.13 5365.32 11967.4
    Capital Lease Obligations 329.246 324.263 356.177 319.949 291.359
    Deferred Income Tax 623.447 831.791 1025.56 881.59 773.501
    Minority Interest 6469.51 8196.51 8530.46 7437.91 6533.45
    Other Liabilities, Total 661.88 880.146 915.477 902.433 579.924
    Total Equity 29989.3 29747 30214.2 30291.1 24575.6
    Common Stock 414.615 414.899 414.942 415.44 415.895
    Retained Earnings (Accumulated Deficit) 19372.6 19070.3 19267.9 17926.7 11801
    Treasury Stock - Common -1626.77 -1432.48 -1378.6 -689.347 -469.944
    Total Liabilities & Shareholders’ Equity 65640.9 64064.3 64934.5 60543.3 56206.7
    Total Common Shares Outstanding 18809.2 18468.1 18815.2 18839.6 18861.5
    Additional Paid-In Capital 12420.3 12461.4 12465.8 12555.7 12668.7
    Unrealized Gain (Loss) 59.346 93.701 271.418 533.078 517.148
    Other Equity, Total -650.759 -860.86 -827.306 -450.393 -357.207
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 5778.6 18572.7 5013.04 5583.82 11429.1
    Cash From Operating Activities 6265.15 5366.29 5325.34 5324.63 5094.36
    Cash From Operating Activities 906.16 881.414 846.661 634.649 426.151
    Amortization 101.686 89.917 763.491 898.351 727.113
    Non-Cash Items 642.081 -12870.8 -512.005 -399.094 -6875.88
    Cash Taxes Paid 892.085 726.716 959.176 1102.09 838.547
    Cash Interest Paid 339.524 179.623 215.307 339.602 153.264
    Changes in Working Capital -1163.38 -1306.92 -785.855 -1393.09 -612.103
    Cash From Investing Activities -4070.82 -2515.98 -7845.56 -3824.34 -616.1
    Capital Expenditures -1402.68 -1741.06 -1495.16 -1481.14 -1565.7
    Other Investing Cash Flow Items, Total -2668.14 -774.915 -6350.4 -2343.2 949.599
    Cash From Financing Activities -3186.39 -3225.26 2233.19 2800.84 -2177.74
    Financing Cash Flow Items -2014.15 -452.366 -1724.7 -1512.43 -1167.66
    Total Cash Dividends Paid -1267.62 -938.489 -1187.02 -819.688 -710.328
    Issuance (Retirement) of Debt, Net 962.991 -1501.48 5340.28 5165.01 304.665
    Foreign Exchange Effects 47.322 -649.711 280.015 95.054 242.465
    Net Change in Cash -944.732 -1024.66 -7.016 4396.18 2542.99
    Issuance (Retirement) of Stock, Net -867.613 -332.93 -195.373 -32.05 -604.419
    Dec 2022 Jun 2022 Dec 2021 Jun 2021 Mar 2021
    Cash From Operating Activities 6265.15 3948.94 5366.29 2335.55
    Changes in Working Capital 6265.15 3948.94 5366.29 2335.55
    Cash From Investing Activities -4070.82 -5989.66 -2515.98 -4055.97
    Other Investing Cash Flow Items, Total -2827.49 -5362.69 -2515.98 -4055.97
    Cash From Financing Activities -3186.39 -1460.53 -3225.26 -761.689
    Financing Cash Flow Items -3367.9 -249.354 -3225.26 -761.689
    Foreign Exchange Effects 47.322 -32.85 -649.711 -113.766
    Net Change in Cash -944.732 -3534.09 -1024.66 -2595.87
    Capital Expenditures -1243.32 -626.972
    Issuance (Retirement) of Stock, Net -867.613 -809.316
    Issuance (Retirement) of Debt, Net 1049.12 -401.857
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Tse (Eric S Y) Individual Investor 21.5412 4050000000 0 2022-12-31
    France Investment China 1 Group Ltd Corporation 12.1229 2279254761 0 2023-06-30
    Tse (Ping) Individual Investor 8.8207 1658403124 27000000 2023-07-06 LOW
    Cheng (Cheung Ling) Individual Investor 4.718 887034750 7000000 2023-04-04
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.6965 318957763 -1764000 2023-09-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 1.0584 198993951 -5565000 2023-09-30 LOW
    First Sentier Investors (Hong Kong) Limited Investment Advisor 1.0019 188360500 -3018000 2023-07-31 LOW
    Tse (Hsin Stephen) Individual Investor 0.9268 174247000 0 2022-12-31
    Bosera Asset Management Co., Ltd. Investment Advisor 0.7277 136825000 48812000 2023-06-30 MED
    State Street Global Advisors Asia Ltd. Investment Advisor/Hedge Fund 0.6734 126615223 4027416 2023-09-30 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.5832 109645878 -17217700 2022-12-31 LOW
    APG Asset Management N.V. Pension Fund 0.5599 105263158 -13607922 2023-03-31 LOW
    Hang Seng Investment Management Ltd. Investment Advisor 0.4592 86341681 8534944 2023-09-30 LOW
    BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.385 72390477 196000 2023-09-30 LOW
    California Public Employees' Retirement System Pension Fund 0.3818 71777747 -5538000 2022-06-30 LOW
    HSBC Global Asset Management (Hong Kong) Limited Investment Advisor 0.3517 66124984 0 2022-12-31 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.3506 65908990 -5518500 2023-09-30 LOW
    Schroder Investment Management (Hong Kong) Ltd. Investment Advisor/Hedge Fund 0.288 54143000 54143000 2023-07-31 LOW
    China Asset Management Co., Ltd. Investment Advisor 0.2512 47229988 187088 2023-09-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.2365 44458499 0 2023-09-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Sino Biopharmeceutical Company profile

    Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in Modernized Chinese Medicines and Chemical Medicines, Investment, and Others segments. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianqingganping enteric capsules, Tianding tablets, Mingzheng capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Tianqingning injections, and Beraprost Sodium tablets; and oncology medicines consisting of Zhiruo, Saiweijian, Tianqingyitai, and Qingweike injections, as well as Shoufu and Yinishu tablets, and Gelike capsules. The company's principal products also include Analgesic medicines, such as Kaifen injections and Zepusi Flurbiprofen Cataplasms; Orthopedic medicines, which comprise New Ossified Triol capsules and Jiuli tablets; anti-infectious medicines, including Tiance injections and Tianjie tablets; parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and anorectal medicines comprising Aisuping injections and Getai tablets. In addition, it develops medicines for liver, tumor, cardio-cerebral, analgesia, respiratory system, and orthopedic diseases; engages in the retail and distribution of pharmaceutical products; provides medical management consultancy services; and manufactures, sells, and distributes health food products, as well as is involved in optometry for optical glasses and sale of ophthalmic products. Further, the company provides research and development, medical technology development, and outpatient and surgical procedure services. The company was incorporated in 2000 and is headquartered in Wanchai, Hong Kong.
    Industry: Pharmaceuticals (NEC)

    湾仔港湾道1号会展广场辨公大楼41楼09室
    HK

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    BTC/USD

    43,745.10 Price
    +4.060% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    2,021.83 Price
    -0.340% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    XRP/USD

    0.63 Price
    -0.260% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    15,952.50 Price
    +0.810% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading